$39.71
0.06% today
Nasdaq, Nov 26, 04:49 pm CET
ISIN
US9250501064
Symbol
VRNA
Sector
Industry

Verona Pharma plc Sponsored ADR Target price 2024 - Analyst rating & recommendation

Verona Pharma plc Sponsored ADR Classifications & Recommendation:

Buy
100%

Verona Pharma plc Sponsored ADR Price Target

Target Price $45.81
Price $39.68
Potential
Number of Estimates 8
8 Analysts have issued a price target Verona Pharma plc Sponsored ADR 2025 . The average Verona Pharma plc Sponsored ADR target price is $45.81. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 8 Analysts recommend Verona Pharma plc Sponsored ADR to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Verona Pharma plc Sponsored ADR stock has an average upside potential 2025 of . Most analysts recommend the Verona Pharma plc Sponsored ADR stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.00 20.92
100.00%

8 Analysts have issued a sales forecast Verona Pharma plc Sponsored ADR 2024 . The average Verona Pharma plc Sponsored ADR sales estimate is

$20.9m
Unlock
. This is
268.23% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$27.9m 391.20%
Unlock
, the lowest is
$11.3m 98.94%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $0.0 100.00%
2025
$156m 644.26%
Unlock
2026
$306m 96.85%
Unlock
2027
$514m 67.89%
Unlock
2028
$763m 48.33%
Unlock

1 Analyst has issued an EBITDA forecast Verona Pharma plc Sponsored ADR 2024 . The average Verona Pharma plc Sponsored ADR EBITDA estimate is

$-77.4m
Unlock
. This is
50.07% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-77.4m 50.07%
Unlock
, the lowest is
$-77.4m 50.07%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-67.2m 10.55%
2024
$-77.4m 15.26%
Unlock
2025
$-106m 37.34%
Unlock
2026
$-46.1m 56.63%
Unlock
2027
$215m 567.46%
Unlock

EBITDA Margin

2025
-68.29% 81.55%
Unlock
2026
-15.04% 77.98%
Unlock
2027
41.89% 378.52%
Unlock

3 Verona Pharma plc Sponsored ADR Analysts have issued a net profit forecast 2024. The average Verona Pharma plc Sponsored ADR net profit estimate is

$-123m
Unlock
. This is
22.51% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-23.7m 85.05%
Unlock
, the lowest is
$-178m 11.85%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-56.5m 33.65%
2024
$-123m 117.88%
Unlock
2025
$-49.7m 59.61%
Unlock
2026
$-8.2m 83.56%
Unlock
2027
$18.8m 330.35%
Unlock
2028
$39.3m 108.71%
Unlock

Net Margin

2025
-31.92% 94.57%
Unlock
2026
-2.67% 91.64%
Unlock
2027
3.66% 237.08%
Unlock
2028
5.15% 40.71%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.69 -1.50
33.65% 117.39%
P/E negative
EV/Sales 149.91

3 Analysts have issued a Verona Pharma plc Sponsored ADR forecast for earnings per share. The average Verona Pharma plc Sponsored ADR <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.50
Unlock
. This is
22.68% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.29 85.05%
Unlock
, the lowest is
$-2.17 11.86%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.69 33.65%
2024
$-1.50 117.39%
Unlock
2025
$-0.61 59.33%
Unlock
2026
$-0.10 83.61%
Unlock
2027
$0.23 330.00%
Unlock
2028
$0.48 108.70%
Unlock

P/E ratio

Current -20.47 6.36%
2024
-26.39 28.92%
Unlock
2025
-65.35 147.63%
Unlock
2026
-397.60 508.42%
Unlock
2027
172.52 143.39%
Unlock
2028
82.67 52.08%
Unlock

Based on analysts' sales estimates for 2024, the Verona Pharma plc Sponsored ADR stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

149.91
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
155.25
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 552.00 71.83%
2024
149.91 72.84%
Unlock
2025
20.14 86.56%
Unlock
2026
10.23 49.20%
Unlock
2027
6.09 40.44%
Unlock
2028
4.11 32.58%
Unlock

P/S ratio

Current 571.67 76.90%
2024
155.25 72.84%
Unlock
2025
20.86 86.56%
Unlock
2026
10.60 49.20%
Unlock
2027
6.31 40.43%
Unlock
2028
4.26 32.58%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today